Pfizer likely needs more data to bring the efficacy of a single dose of its COVID-19 vaccine into focus, but such a study could solve the dilemma of what to do with patients in the placebo arm of the trial. • Source: illustration from Pfizer briefing document and photo by Dan Kitwood/Getty Images
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
